Unlock Cutting-Edge Insisghts on STAT6 PROTACs
Discover how targeted protein degradation is redefining drug discovery beyond oncology. This in-depth whitepaper showcases BioDuro’s comprehensive in vitro evaluation platform using Kymera’s STAT6 degrader as a case study. From assay development to functional and selectivity testing, get exclusive data and actionable insights that can accelerate your early-stage programs. Fill out the form to download the full report and stay ahead in the TPD revolution.
| 
